Please wait while the formulary information is being retrieved.
MITOXANTRONE HCL (MITOXANTRONE HCL)
- Acute myeloid leukemia
- Metastatic prostate carcinoma
- Relapsing form of multiple sclerosis
- Secondary progressive multiple sclerosis
mitoxantrone 2 mg/mL concentrate,intravenous
- Dosage information is not available
2 mg/mL concentrate,intravenous
- Dosage information is not available
Acute myeloid leukemia
- Infuse 12 mg/m2 by intravenous route once daily on days 1 through 3 of treatment cycle
- Infuse 12 mg/m2 by intravenous route once daily on days 1 and 2 of treatment cycle
Metastatic prostate carcinoma
- Infuse 12 mg/m2 over 5-15 minute(s) by intravenous route every 3 weeks
- Infuse 14 mg/m2 over 5-15 minute(s) by intravenous route every 3 weeks
- adenovirus vac live type-4 & 7
- adenovirus vaccine live type-4
- adenovirus vaccine live type-7
- BCG vaccine, live (PF)
- flu vac,qval 2013-14 (2-49yrs)
- Flumist 2013-2014
- M-m-r Ii (pf)
- measles,mumps&rubella vacc(PF)
- measles,mumps,rub,varicel(PF)
- natalizumab
- Proquad (pf)
- Rotateq Vaccine
- rotavirus vaccine live, penta
- typhoid vaccine
- Tysabri
- varicella virus vacc live (PF)
- Varivax (pf)
- Vivotif Berna Vaccine
- yellow fever vaccine live (PF)
- Yf-vax (pf)
- Zostavax (pf)
- zoster vaccine live (PF)
Contraindicated
- ado-trastuzumab emtansine
- clozapine
- Clozaril
- deferiprone
- Fazaclo
- Ferriprox
- Herceptin
- Kadcyla
- trastuzumab
- Versacloz
Severe
Moderate
- None
- Lactating mother
- Severe hepatic disease
- Severe neutropenic disorder
Contraindicated
- Acute coronary syndrome
- Acute myocardial infarction
- Anemia
- Bacterial infection
- Bone marrow depression
- Chronic heart failure
- Congenital heart disease
- Coronary artery disease
- Disease of liver
- Fungal infection
- Left ventricular failure
- Leukopenia
- Neutropenic disorder
- Peripheral vascular disease
- Pregnancy
- Secondary acute myeloid leukemia
- Severe infection
- Thrombocytopenic disorder
- Thromboembolic disorder
Severe
Moderate
- Seizure disorder
MITOXANTRONE HCL (MITOXANTRONE HCL)
- Acute myeloid leukemia
- Metastatic prostate carcinoma
- Relapsing form of multiple sclerosis
- Secondary progressive multiple sclerosis
- Abdominal pain with cramps
- Cough
- Dyspnea
- Gastrointestinal hemorrhage
- Infection
- Leukopenia
- Stomatitis
- Alopecia
- Amenorrhea
- Diarrhea
- General weakness
- Headache disorder
- Menstrual disorder
- Nausea
- Pharyngitis
- Rhinitis
- Upper respiratory infection
- Urinary tract infection
- Urine discoloration
- Vomiting
More Frequent
Severe
Less Severe
- Cardiac arrhythmia
- Chronic heart failure
- Conjunctivitis
- Jaundice
- Renal failure
- Seizure disorder
- Thrombocytopenic disorder
- Anemia
- Back pain
- Blue sclera
- Sinusitis
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Anaphylaxis
- Hypotension
- Injection site sequelae
- Interstitial pneumonitis
- Left ventricular failure
- Phlebitis after infusion
- Secondary acute myeloid leukemia
- Severe neutropenic disorder
- Skin rash
- Urticaria
Less Severe
- Bone pain
- Chest pain
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Mitoxantrone
Safety and efficacy not established.
- 1 Day – 18 Years
- Safety and efficacy not established.
Mitoxantrone Hydrochloride
- Severity Level:
D
- Additional Notes:
Contraindicated
Mitoxantrone
Prolonged,high drug levels in breastmilk:Discontinue nursing before treatment
| General | Excretion Potential | Effect on Infant | Notes |
| Drug should not be given to breast feeding mothers | Excreted | Not known; no or inclusive data | Prolonged,high drug levels in breastmilk:Discontinue nursing before treatment |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
Mitoxantrone
Elderly may have decreased drug clearance and therefore increased risk of adverse reactions.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | N | Y | Y | N | N | N |
BEERS: N HEDIS: N STOPP: N
No Known Risk
None
- Mitoxantrone must be given only by injection into a vein. Do not give by injection into a muscle, under the skin, or into the spinal cord. If this medication accidentally leaks into the skin/muscle around the injection site, it may cause severe damage.<br /><br />Tell your doctor right away if you notice redness, pain, or swelling at or near the injection site. This medication may rarely cause serious (rarely fatal) heart problems (including heart failure). This effect may occur during treatment or months to years after treatment is completed.<br /><br />The risk of heart problems is affected by your dose, medical history (including previous heart disease, radiation treatment to the chest area, or if you have MS-multiple sclerosis), and previous use of this and other drugs (including doxorubicin or daunorubicin). Tell your doctor right away if you notice symptoms such as irregular heartbeat, shortness of breath, swelling ankles/feet, unusual tiredness, or unusual/sudden weight gain. Very rarely, people who are treated with this type of medication have developed new cancers (e.g., secondary leukemia).<br /><br /> The risk may be increased when this medication is given with certain anti-cancer drugs or radiation treatment. Consult your doctor for more details. Laboratory and/or medical tests (e.g., complete blood count, heart/liver function tests, ECG) should be performed before starting treatment and periodically to monitor your progress or check for side effects. Consult your doctor for more details.
| Acute myeloid leukemia | |
| C92.0 | Acute myeloblastic leukemia |
| C92.00 | Acute myeloblastic leukemia, not having achieved remission |
| C92.02 | Acute myeloblastic leukemia, in relapse |
| C92.4 | Acute promyelocytic leukemia |
| C92.40 | Acute promyelocytic leukemia, not having achieved remission |
| C92.42 | Acute promyelocytic leukemia, in relapse |
| C92.5 | Acute myelomonocytic leukemia |
| C92.50 | Acute myelomonocytic leukemia, not having achieved remission |
| C92.52 | Acute myelomonocytic leukemia, in relapse |
| C92.6 | Acute myeloid leukemia with 11q23-abnormality |
| C92.60 | Acute myeloid leukemia with 11q23-abnormality not having achieved remission |
| C92.62 | Acute myeloid leukemia with 11q23-abnormality in relapse |
| C93.0 | Acute monoblastic/monocytic leukemia |
| C93.00 | Acute monoblastic/monocytic leukemia, not having achieved remission |
| C93.02 | Acute monoblastic/monocytic leukemia, in relapse |
| C94.4 | Acute panmyelosis with myelofibrosis |
| C94.40 | Acute panmyelosis with myelofibrosis not having achieved remission |
| C94.42 | Acute panmyelosis with myelofibrosis, in relapse |
| Metastatic prostate carcinoma | |
| C61 | Malignant neoplasm of prostate |
| Relapsing form of multiple sclerosis | |
| G35 | Multiple sclerosis |
| Secondary progressive multiple sclerosis | |
| G35 | Multiple sclerosis |
| 0-9 | A-Z |
|---|---|
| C61 | Malignant neoplasm of prostate |
| C92.0 | Acute myeloblastic leukemia |
| C92.00 | Acute myeloblastic leukemia, not having achieved remission |
| C92.02 | Acute myeloblastic leukemia, in relapse |
| C92.4 | Acute promyelocytic leukemia |
| C92.40 | Acute promyelocytic leukemia, not having achieved remission |
| C92.42 | Acute promyelocytic leukemia, in relapse |
| C92.5 | Acute myelomonocytic leukemia |
| C92.50 | Acute myelomonocytic leukemia, not having achieved remission |
| C92.52 | Acute myelomonocytic leukemia, in relapse |
| C92.6 | Acute myeloid leukemia with 11q23-abnormality |
| C92.60 | Acute myeloid leukemia with 11q23-abnormality not having achieved remission |
| C92.62 | Acute myeloid leukemia with 11q23-abnormality in relapse |
| C93.0 | Acute monoblastic/monocytic leukemia |
| C93.00 | Acute monoblastic/monocytic leukemia, not having achieved remission |
| C93.02 | Acute monoblastic/monocytic leukemia, in relapse |
| C94.4 | Acute panmyelosis with myelofibrosis |
| C94.40 | Acute panmyelosis with myelofibrosis not having achieved remission |
| C94.42 | Acute panmyelosis with myelofibrosis, in relapse |
| G35 | Multiple sclerosis |
| G35 | Multiple sclerosis |
Formulary Reference Tool